β-Amyloid-mediated vasoactivity and vascular endothelial damage
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Deposits of beta-amyloid are apparent in ageing and Alzheimer's disease, but the role of this peptide in neurodegeneration is unclear. The free-radical theory of ageing may also account for Alzheimer-type degeneration and consequently links between free-radical generation and beta-amyloid have been sought. We demonstrate here that beta-amyloid interacts with endothelial cells on blood vessels to produce and excess of superoxide radicals, with attendant alterations in endothelial structure and function. The superoxide radical can scavenge endothelium-derived relaxing factor and produce potent oxidizing agents, which can cause lipid peroxidation and other degenerative changes. The alterations in vascular tone and endothelial damage are prevented by the oxygen-radical-scavenging enzyme superoxide dismutase. These observations suggest a normal vasoactive role for beta-amyloid as well as a mechanism by which beta-amyloid may play a role in vascular abnormalities and neurodegeneration mediated by free radicals.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Aβ is a potent vasoconstrictor113,114 and suppresses endothelium-dependent responses, functional hyperemia, and cerebrovascular autoregulation.115–117”
In the citing paper
“As shown by pharmacological studies, these high concentrations of A b may impair local BBB integrity (58-59), which in turn may contaminate brain ISF with blood and/or plasma that possesses A b -degrading activity (48)”
From Clearance of Alzheimer’s amyloid-β1-40 peptide from brain by LDL receptor–related protein-1 at the blood-brain barrier (2000) · cites this paper as [59]
In the citing paper
“Aβ4 constrict isolated cerebral and systemic blood vessels (Niwa et al., 2001; Paris et al., 2003; Thomas et al., 1996)”
From The Pathobiology of Vascular Dementia (2013) · cites this paper as Thomas et al., 1996
Citations
Cites
Furchgott, R. F., & Zawadzki, J. V. (1980) · Nature · doi:10.1038/288373a0 · Cited by 12,064
Lipton, S. A., Choi, Y.-B., Pan, Z.-H., Lei, S. Z., Chen, H.-S. V., Sucher, N. J., Loscalzo, J., Singel, D. J., & Stamler, J. S. (1993) · Nature · doi:10.1038/364626a0 · Cited by 2,433
Neurotrophic and Neurotoxic Effects of Amyloid β Protein: Reversal by Tachykinin Neuropeptides
Yankner, B. A., Duffy, L. K., & Kirschner, D. A. (1990) · Science · doi:10.1126/science.2218531 · Cited by 1,975
Alzheimer's disease and Down's syndrome: Sharing of a unique cerebrovascular amyloid fibril protein
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(84)91209-9 · Cited by 1,693
β-Amyloid precursor protein metabolites and loss of neuronal Ca2+ homeostasis in Alzheimer's disease
Mattson, M. P., Barger, S. W., Cheng, B., Lieberburg, I., Smith-Swintosky, V. L., & Rydel, R. E. (1993) · Trends in Neurosciences · doi:10.1016/0166-2236(93)90009-b · Cited by 518
PGH synthase and lipoxygenase generate superoxide in the presence of NADH or NADPH.
Kukreja, R. C., Kontos, H. A., Hess, M. L., & Ellis, E. F. (1986) · Circulation Research · doi:10.1161/01.res.59.6.612 · Cited by 487
Bu�e, L., Hof, P. R., Bouras, C., Delacourte, A., Perl, D. P., Morrison, J. H., & Fillit, H. M. (1994) · Acta Neuropathologica · doi:10.1007/bf00294173 · Cited by 334
Scholz, W. (1938) · Zeitschrift für die gesamte Neurologie und Psychiatrie · doi:10.1007/bf02890989 · Cited by 180
Soluble β-Amyloid Induction of Alzheimer's Phenotype for Human Fibroblast K + Channels
Etcheberrigaray, R., Ito, E., Kim, C. S., & Alkon, D. L. (1994) · Science · doi:10.1126/science.8146663 · Cited by 167
Untangling the pathophysio-chemistry of β-amyloid
Mattson, M. P. (1995) · Nature Structural & Molecular Biology · doi:10.1038/nsb1195-926 · Cited by 41
Research works printed but not linked: 2
- Davignon, J., Gregg, R. & Sing, C. Atherosclerosis 8, 1–21 (1988).
- Tomimoto, H., Nakimura, S., Wakita, H., Kimura, J. & Akiguchi, I. J. Cereb. Blood Flow Metab. 14, 563–573 (1994).
Cited by
Items 101–200 of 710
Alzheimer's Disease: Redox Dysregulation As a Common Denominator for Diverse Pathogenic Mechanisms
von Bernhardi, R., & Eugenín, J. (2012) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.4082 · Cited by 190
Age-dependent cerebrovascular dysfunction in a transgenic mouse model of cerebral amyloid angiopathy
Shin, H. K., Jones, P. B., Garcia-Alloza, M., Borrelli, L., Greenberg, S. M., Bacskai, B. J., Frosch, M. P., Hyman, B. T., Moskowitz, M. A., & Ayata, C. (2007) · Brain · doi:10.1093/brain/awm156 · Cited by 195
“The latter view is supported by experimental data showing vascular impairment by Ab and in transgenic mouse models of AD and CAA (Thomas et al., 1996; Crawford et al., 1998; Iadecola et al., 1999; Niwa et al., 2000a, 2001; Paris et al., 2003).”
BackgroundCerebral amyloid angiopathy: An overview
Yamada, M. (2000) · Neuropathology · doi:10.1046/j.1440-1789.2000.00268.x · Cited by 191
Alzheimer’s Disease: The Link Between Amyloid-β and Neurovascular Dysfunction
Solis, Hascup, K. N., & Hascup, E. R. (2020) · Journal of Alzheimer's Disease · doi:10.3233/jad-200473 · Cited by 178
Niwa, K., Carlson, G. A., & Iadecola, C. (2000) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-200012000-00005 · Cited by 191
McCusker, S. M., Curran, M. D., Dynan, K. B., McCullagh, C. D., Urquhart, D. D., Middleton, D., Patterson, C. C., McIlroy, S. P., & Peter Passmore, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04008-3 · Cited by 191
The Alzheimer’s Disease Amyloid-Beta Hypothesis in Cardiovascular Aging and Disease
Stakos, D. A., Stamatelopoulos, K., Bampatsias, D., Sachse, M., Zormpas, E., Vlachogiannis, N. I., Tual-Chalot, S., & Stellos, K. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.12.033 · Cited by 188
“The Tg2576 mouse model expresses 5 times the levels of endogenous murine APP (56) and shows progressive impairment of cognitive function together with Ab1-40–dependent (57) and ROSmediated (53,58) endothelial dysfunction, impaired vascular reactivity, and 30% attenuation in cerebral blood flow (59).”
BackgroundClearance of amyloid β-peptide from brain: transport or metabolism?
Zlokovic, B. V., Yamada, S., Holtzman, D., Ghiso, J., & Frangione, B. (2000) · Nature Medicine · doi:10.1038/77397 · Cited by 186
“remains unclear, as the peptide was studied at very high concentrations of about 240 μm/l, which may impair blood–brain barrier integrit”
BackgroundTohidpour, A., Morgun, A. V., Boitsova, E. B., Malinovskaya, N. A., Martynova, G. P., Khilazheva, E. D., Kopylevich, N. V., Gertsog, G. E., & Salmina, A. B. (2017) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2017.00276 · Cited by 178
“Accumulation of β-amyloid is also related to endothelial dysfunction, vasoconstriction and regional cerebral hypoperfusion of damaged cerebral vessels in AD (Thomas et al., 1996; Niwa et al., 2000; Suter et al., 2002; Townsend et al., 2002; Smith and Greenberg, 2009).”
BackgroundFrom Chronic Cerebral Hypoperfusion to Alzheimer-Like Brain Pathology and Neurodegeneration
Zhao, Y., & Gong, C.-X. (2015) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-014-0127-9 · Cited by 180
“The Ab deposition in small arteries caused by CCH could further induce cerebrovascular lesion (Thomas et al. 1996) and worsen cerebral hypoperfusion and finally lead to a vicious circle and irreversible damages.”
Kumar-Singh, S., Pirici, D., McGowan, E., Serneels, S., Ceuterick, C., Hardy, J., Duff, K., Dickson, D., & Van Broeckhoven, C. (2005) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)62995-1 · Cited by 184
Hypertension and cognitive function: Pathophysiologic effects of hypertension on the brain
Manolio, T. A., Olson, J., & Longstreth, W. T. (2003) · Current Hypertension Reports · doi:10.1007/s11906-003-0029-6 · Cited by 177
Vitamin C Status and Cognitive Function: A Systematic Review
Travica, N., Ried, K., Sali, A., Scholey, A., Hudson, I., & Pipingas, A. (2017) · Nutrients · doi:10.3390/nu9090960 · Cited by 170
Yang, S.-P., Bae, D.-G., Kang, H. J., Gwag, B. J., Gho, Y. S., & Chae, C.-B. (2004) · Neurobiology of Aging · doi:10.1016/s0197-4580(03)00111-8 · Cited by 169
“Most cases of AD are accompanied by cerebrovascular pathologies, such as cerebral amyloid angiopathy, endothelial degeneration, and hypoperfusion [5,17,39].”
BackgroundHooijmans, C. R., Van der Zee, C. E. E. M., Dederen, P. J., Brouwer, K. M., Reijmer, Y. D., van Groen, T., Broersen, L. M., Lütjohann, D., Heerschap, A., & Kiliaan, A. J. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.12.002 · Cited by 171
“This decrease in rCBV, likely causing hypoperfusion of the brain, may be caused by an aggravation of the vasoconstriction induced by Aβ depositions (Niwa et al., 2001; Shin et al., 2007; Thomas et al., 1996).”
Status of Risk Factors for Vascular Dementia
Skoog, I. (1998) · Neuroepidemiology · doi:10.1159/000026147 · Cited by 178
Marco, S., & Skaper, S. D. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2006.03.047 · Cited by 172
Blood pressure and the risk for dementia—A double edged sword
Kennelly, S. P., Lawlor, B. A., & Kenny, R. A. (2009) · Ageing Research Reviews · doi:10.1016/j.arr.2008.11.001 · Cited by 173
Mechanism of Cerebral β-Amyloid Angiopathy: Murine and Cellular Models
Herzig, M. C., Nostrand, W. E., & Jucker, M. (2006) · Brain Pathology · doi:10.1111/j.1750-3639.2006.tb00560.x · Cited by 169
Cerebral amyloid angiopathy and thrombolysis-related intracerebral haemorrhage
McCarron, M. O., & Nicoll, J. A. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00825-7 · Cited by 169
Cell‐specific blood–brain barrier regulation in health and disease: a focus on hypoxia
Engelhardt, S., Patkar, S., & Ogunshola, O. O. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12489 · Cited by 168
“The reason for this phenomenon is unclear but could be explained partly by the anti-angiogenic activity of Aβ (Thomas et al., 1996).”
BackgroundDebette, S., Bombois, S., Bruandet, A., Delbeuck, X., Lepoittevin, S., Delmaire, C., Leys, D., & Pasquier, F. (2007) · Stroke · doi:10.1161/strokeaha.107.488403 · Cited by 168
Brain Microvascular Changes in Alzheimer's Disease and Other Dementiasa
BUÉE, L., HOF, P. R., & DELACOURTE, A. (1997) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1997.tb48457.x · Cited by 165
Impaired Aβ clearance: a potential link between atherosclerosis and Alzheimer’s disease
Gupta, A., & Iadecola, C. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00115 · Cited by 157
Low plasma vitamin C in Alzheimer patients despite an adequate diet
Rivi�re, S., Birlouez-Aragon, I., Nourhash�mi, F., & Vellas, B. (1998) · International Journal of Geriatric Psychiatry · doi:10.1002/(sici)1099-1166(1998110)13:11<749::aid-gps860>3.0.co;2-t · Cited by 163
“Psychiatry 13, 749±754 (1998) with blood vessels (Thomas et al., 1996).”
BackgroundRegulated Formation of an Amyloid-like Translational Repressor Governs Gametogenesis
Berchowitz, L. E., Kabachinski, G., Walker, M. R., Carlile, T. M., Gilbert, W. V., Schwartz, T. U., & Amon, A. (2015) · Cell · doi:10.1016/j.cell.2015.08.060 · Cited by 165
“In addition to depleting functional proteins, amyloids are thought to interfere with cellular functions (Thomas et al., 1996), cause cell death (Loo et al.”
Harris, S. S., Wolf, F., De Strooper, B., & Busche, M. A. (2020) · Neuron · doi:10.1016/j.neuron.2020.06.005 · Cited by 161
“In turn, there is long-standing evidence that Ab exerts vasoactive effects (Thomas et al., 1996), with more recent work indicating that Ab induces pericyte-mediated capillary constriction (Nortley et al., 2019) that may underpin the large decreases in cerebral blood flow (CBF) often observed in…”
BackgroundAnti-inflammatory Drugs Protect Against Alzheimer Disease at Low Doses
Broe, G. A., Grayson, D. A., Creasey, H. M., Waite, L. M., Casey, B. J., Bennett, H. P., Brooks, W. S., & Halliday, G. M. (2000) · Archives of Neurology · doi:10.1001/archneur.57.11.1586 · Cited by 160
Nutritional influences on cognitive function: mechanisms of susceptibility
Leigh Gibson, E., & Green, M. W. (2002) · Nutrition Research Reviews · doi:10.1079/nrr200131 · Cited by 159
“Biochemical and physiological studies implicate oxidative damage to the central nervous system microvasculature in the aetiology of neurodegenerative diseases, including Alzheimer’s disease (Richardson, 1993; Thomas et al. 1996).”
BackgroundPathogenesis of cerebral amyloid angiopathy
Rensink, A. A. M., de Waal, R. M. W., Kremer, B., & Verbeek, M. M. (2003) · Brain Research Reviews · doi:10.1016/j.brainresrev.2003.08.001 · Cited by 159
Microglia, Scavenger Receptors, and the Pathogenesis of Alzheimer’s Disease
El Khoury, J., Hickman, S. E., Thomas, C. A., Loike, J. D., & Silverstein, S. C. (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00036-0 · Cited by 159
Carlson, G. A., Borchelt, D. R., Dake, A., Turner, S., Danielson, V., Coffin, J. D., Eckman, C., Meiners, J., Nilsen, S. P., Younkin, S. G., et al. (1997) · Human Molecular Genetics · doi:10.1093/hmg/6.11.1951 · Cited by 158
“If Aβ peptide causes endothelial damage leading to lowered levels of endothelial-derived vascular relaxing factor (40), the increased vascular smooth muscle of FGF2 transgenic mice could lead to further decreases in blood flow due to enhanced vasoconstriction.”
BackgroundDorr, A., Sahota, B., Chinta, L. V., Brown, M. E., Lai, A. Y., Ma, K., Hawkes, C. A., McLaurin, J., & Stefanovic, B. (2012) · Brain · doi:10.1093/brain/aws243 · Cited by 153
“…the compromise in vascular function may be related not only to the development of cerebral amyloid angiopathy but also to amyloid-b-induced vasoactivity, endothelial and pericyte damage or oxidative stress (Thomas et al., 1996; Verbeek et al., 1997; Butterfield, 2002; Carrano et al., 2011).”
BackgroundAkisaki, T., Sakurai, T., Takata, T., Umegaki, H., Araki, A., Mizuno, S., Tanaka, S., Ohashi, Y., Iguchi, A., Yokono, K., et al. (2006) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.632 · Cited by 152
New Therapeutic Targets in the Neurovascular Pathway in Alzheimer's Disease
Zlokovic, B. V. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.05.011 · Cited by 151
“Amyloid -peptide is a potent vasoconstrictor in brain.(24) In mice expressing A -precursor protein (App), reductions in endothelium-dependent regulation of cortical microcirculation(25) and CBF dysregulation in response to brain activation have been reported prior to neuropathological changes.”
BackgroundZhu, Y. J., Lin, H., & Lal, R. (2000) · The FASEB Journal · doi:10.1096/fasebj.14.9.1244 · Cited by 152
Histochemical detection of 4-hydroxynonenal protein in Alzheimer amyloid
Ando, Y., Brännström, T., Uchida, K., Nyhlin, N., Näsman, B., Suhr, O. B., Yamashita, T., Olsson, T., Salhy, M. E., Uchino, M., et al. (1998) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(98)00042-2 · Cited by 164
Scuteri, A., Nilsson, P. M., Tzourio, C., Redon, J., & Laurent, S. (2011) · Journal of Hypertension · doi:10.1097/hjh.0b013e328347cc17 · Cited by 151
Oxidative processes in Alzheimer's disease: the role of Aβ-metal interactions
Lynch, T., Cherny, R. A., & Bush, A. I. (2000) · Experimental Gerontology · doi:10.1016/s0531-5565(00)00112-1 · Cited by 168
Beckmann, N., Schuler, A., Mueggler, T., Meyer, E. P., Wiederhold, K.-H., Staufenbiel, M., & Krucker, T. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-24-08453.2003 · Cited by 149
“Although fibril formation of A, leading to neurodegeneration and death, has constituted an important paradigm in AD research (Hardy and Higgins, 1992), soluble A peptides display free radical-mediated vasoactive properties ( Thomas et al., 1996 ) and have been shown recently to elicit vasoconstriction of vessels as la…”
BackgroundD'Andrea, M., & Nagele, R. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206775474224 · Cited by 146
Contemplating Alzheimer’s Disease and the Contribution of White Matter Hyperintensities
Brickman, A. M. (2013) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-013-0415-7 · Cited by 141
Goulay, R., Romo, L. M., Hol, E. M., & Dijkhuizen, R. M. (2019) · Translational Stroke Research · doi:10.1007/s12975-019-00755-2 · Cited by 159
Cerebrovascular Reactivity to Carbon Dioxide in Alzheimer's Disease
Glodzik, L., Randall, C., Rusinek, H., & de Leon, M. J. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-122011 · Cited by 153
“It has been shown that A increased vasoconstriction of rat aorta pretreated with the vasoconstrictor phenylepinephrine [38] or endothelin-1 [39].”
BackgroundAtherosclerosis and Alzheimer - diseases with a common cause? Inflammation, oxysterols, vasculature
Lathe, R., Sapronova, A., & Kotelevtsev, Y. (2014) · BMC Geriatrics · doi:10.1186/1471-2318-14-36 · Cited by 137
Role of Hydrogen Peroxide in the Aetiology of Alzheimer??s Disease: Implications for Treatment
Milton, N. G. N. (2004) · Drugs & Aging · doi:10.2165/00002512-200421020-00002 · Cited by 158
Association of plasma amyloid β with risk of dementia: The prospective Three-City Study
Lambert, J. C., Schraen-Maschke, S., Richard, F., Fievet, N., Rouaud, O., Berr, C., Dartigues, J. F., Tzourio, C., Alpérovitch, A., Buée, L., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181b78448 · Cited by 138
Magnetic resonance imaging of anatomic and vascular characteristics in a canine model of human aging
Su, M., Head, E., Brooks, W. M., Wang, Z., Muggenburg, B. A., Adam, G. E., Sutherland, R. J., Cotman, C. W., & Nalcioğlu, O. (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00081-5 · Cited by 141
Statins as potential therapeutic agents in neuroinflammatory disorders
Stüve, O., Youssef, S., Steinman, L., & Zamvil, S. S. (2003) · Current Opinion in Neurology · doi:10.1097/01.wco.0000073942.19076.d1 · Cited by 141
Oxidative stress: A bridge between Down's syndrome and Alzheimer's disease
Zana, M., Janka, Z., & Kalman, J. L. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.03.008 · Cited by 155
“Serum A can interact with endothelial cells in the lood vessels to produce an excess of ROS, with attendant lterations in endothelial structure and function, suggesting a ormal vasoactive role for A and a mechanism by which A an play a role in the vascular abnormalities (atherosclerosis) nd neurodegeneration mediated…”
BackgroundChristie, R. H., Yamada, M., Moskowitz, M. A., & Hyman, B. T. (2001) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64053-9 · Cited by 147
Thal, D. R., Capetillo-Zarate, E., Larionov, S., Staufenbiel, M., Zurbruegg, S., & Beckmann, N. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.01.017 · Cited by 138
Di Luca, M. (1998) · Archives of Neurology · doi:10.1001/archneur.55.9.1195 · Cited by 142
Dehydroepiandrosterone, glucose-6-phosphate dehydrogenase, and longevity
Schwartz, A., & Pashko, L. L. (2004) · Ageing Research Reviews · doi:10.1016/j.arr.2003.05.001 · Cited by 145
Aleshkov, S., Abraham, C. R., & Zannis, V. I. (1997) · Biochemistry · doi:10.1021/bi9626362 · Cited by 138
Preston, J. E., Hipkiss, A. R., Himsworth, D. T. J., Romero, I. A., & Abbott, J. N. (1998) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00058-5 · Cited by 153
Oligodendrocytes damage in Alzheimer's disease: Beta amyloid toxicity and inflammation
ROTH, A. D., RAMÍREZ, G., ALARCÓN, R., & VON BERNHARDI, R. (2005) · Biological Research · doi:10.4067/s0716-97602005000400011 · Cited by 131
Cholesterol in Alzheimers Disease: Unresolved Questions
Stefani, M., & Liguri, G. (2009) · Current Alzheimer Research · doi:10.2174/156720509787313899 · Cited by 133
Fibrin mechanisms and functions in nervous system pathology.
Adams, R. A., Passino, M. A., Sachs, B. D., Nuriel, T., & Akassoglou, K. (2004) · PubMed · doi:10.1124/mi.4.3.6 · Cited by 137
Alzheimer's Mechanisms in Ischemic Brain Degeneration
Pluta, R., Ułamek, M., & Jabłoński, M. (2009) · The Anatomical Record · doi:10.1002/ar.21018 · Cited by 133
“The initial b-amyloid peptide deposits will cause degeneration of ischemic endothelial and pericyte cells, which may compromise the blood-brain barrier (Thomas et al., 1996; Lupo et al., 2001; Anfuso et al., 2004).”
BackgroundAlzheimer disease and platelets: how’s that relevant
Catricala, S., Torti, M., & Ricevuti, G. (2012) · Immunity & Ageing · doi:10.1186/1742-4933-9-20 · Cited by 130
Innate immunity receptor CD36 promotes cerebral amyloid angiopathy
Park, L., Zhou, J., Zhou, P., Pistick, R., El Jamal, S., Younkin, L., Pierce, J., Arreguin, A., Anrather, J., Younkin, S. G., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1300021110 · Cited by 130
Han, B. H., Zhou, M.-L., Johnson, A. W., Singh, I., Liao, F., Vellimana, A. K., Nelson, J. W., Milner, E., Cirrito, J. R., Basak, J., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1414930112 · Cited by 131
Structural neuroimaging in Alzheimer's disease: do white matter hyperintensities matter?
Brickman, A. M., Muraskin, J., & Zimmerman, M. E. (2009) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2009.11.2/ambrickman · Cited by 125
Absence of Vascular Dementia in an Autopsy Series from a Dementia Clinic
Nolan, K. A., Lino, M. M., Seligmann, A. W., & Blass, J. P. (1998) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1998.tb01076.x · Cited by 130
Amyloid β-peptide and oxidative cellular injury in Alzheimer’s disease
Mark, R. J., Blanc, E. M., & Mattson, M. P. (1996) · Molecular Neurobiology · doi:10.1007/bf02755589 · Cited by 146
Stamatelopoulos, K. S., Sibbing, D., Rallidis, L. S., Georgiopoulos, G. A., Stakos, D., Braun, S., Gatsiou, A., Sopova, K., Kotakos, C., Varounis, C., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.12.035 · Cited by 134
Aspirin and non-steroidal anti-inflammatory drugs inhibit amyloid-β aggregation
Thomas, T., Nadackal, T. G., & Thomas, K. (2001) · Neuroreport · doi:10.1097/00001756-200110290-00024 · Cited by 127
Self-citationParis, D., Humphrey, J., Quadros, A., Patel, N., Crescentini, R., Crawford, F., & Mullan, M. (2003) · Neurological Research · doi:10.1179/016164103101201940 · Cited by 127
Self-citationCauses and consequences of baseline cerebral blood flow reductions in Alzheimer’s disease
Bracko, O., Cruz Hernández, J. C., Park, L., Nishimura, N., & Schaffer, C. B. (2021) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x20982383 · Cited by 124
Divino da Rocha, M., Pereira Dias Viegas, F., Cristina Campos, H., Carolina Nicastro, P., Calve Fossaluzza, P., Alberto Manssour Fraga, C., J. Barreiro, E., & Viegas, C. (2011) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152711794480429 · Cited by 126
Xu, J., Chen, S., Ku, G., Ahmed, S. H., Xu, J., Chen, H., & Hsu, C. Y. (2001) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-200106000-00008 · Cited by 128
“, 1999), the molecular mechanism of A -induced toxicity to CECs has not been fully explored but may involve formation of oxygen radicals (Harris et al., 1995; Thomas et al., 1996), inhibition of nitric oxide (NO) production (Sutton et al.”
BackgroundInfluentialThe Apolipoprotein E ε4 Allele and Outcome in Cerebrovascular Disease
McCarron, M. O., Muir, K. W., Weir, C. J., Dyker, A. G., Bone, I., Nicoll, J. A. R., & Lees, K. R. (1998) · Stroke · doi:10.1161/01.str.29.9.1882 · Cited by 127
Poduslo, J. F., Curran, G. L., Wengenack, T. M., Malester, B., & Duff, K. (2001) · Neurobiology of Disease · doi:10.1006/nbdi.2001.0402 · Cited by 121
Mattson, M. P., Begley, J. G., Mark, R. J., & Furukawa, K. (1997) · Brain Research · doi:10.1016/s0006-8993(97)00824-x · Cited by 131
Hooijmans, C. R., Graven, C., Dederen, P. J. W. C., Tanila, H., van Groen, T., & Kiliaan, A. J. (2007) · Brain Research · doi:10.1016/j.brainres.2007.08.063 · Cited by 130
Amyloid-beta and tau protein beyond Alzheimer’s disease
Abyadeh, M., Gupta, V., Paulo, J. A., Mahmoudabad, A. G., Shadfar, S., Mirshahvaladi, S., Gupta, V. B., Nguyen, C. T. O., Finkelstein, D. I., You, Y., et al. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.386406 · Cited by 133
“…a vasoactive role has been suggested for Aβ, which reduces acetylcholine-induced relaxation, enhances contraction of blood vessels, and reduces cerebral blood flow, and pretreatment with superoxide dismutase significantly resolved Aβ-related effects (Thomas et al., 1996; Iadecola et al., 1999).”
BackgroundBlood-Based Proteomic Biomarkers of Alzheimer’s Disease Pathology
Baird, A. L., Westwood, S., & Lovestone, S. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00236 · Cited by 119
Poon, H. F., Joshi, G., Sultana, R., Farr, S. A., Banks, W. A., Morley, J. E., Calabrese, V., & Butterfield, D. A. (2004) · Brain Research · doi:10.1016/j.brainres.2004.05.048 · Cited by 127
“Also, Ah-induced damage can be modulated by the enzyme superoxide dismutase (SOD), suggesting O2 S is involved in Ah toxicity [102].”
BackgroundBriššová, M., Shostak, A., Fligner, C. L., Revetta, F. L., Washington, M. K., Powers, A. C., & Hull, R. L. (2015) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155415573324 · Cited by 130
“Based on data from the Alzheimer’s disease-related peptide Aβ, endothelial cells are susceptible to toxicity by amyloidogenic peptides (Preston et al. 1998; Thomas et al. 1996), and amyloid deposition in the brain of subjects with Alzheimer’s disease is associated with altered endothelial structure (Thomas et al.”
BackgroundInfluentialEwers, M., Zhong, Z., Bürger, K., Wallin, A., Blennow, K., Teipel, S. J., Shen, Y., & Hampel, H. (2008) · Brain · doi:10.1093/brain/awn034 · Cited by 119
“…have shown that damage of the endothelium of the cerebral capillary microvasuculature is a frequently observed brain abnormality in Alzheimer's disease subjects (Bailey et al., 2004) and has been associated with Ab (Thomas et al., 1996; Deane et al., 2003; de la Torre, 2004; Zlokovic, 2005).”
BackgroundEndothelial Dysfunction and Amyloid-β-Induced Neurovascular Alterations
Koizumi, K., Wang, G., & Park, L. (2016) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-015-0256-9 · Cited by 118
“These vascular effects have been attributed to Ab, a key pathogenic factor in AD, which potently constricts blood vessels and impairs the fundamental mechanisms controlling the cerebral circulation (Iadecola 2013; Iadecola et al. 1999; Thomas et al. 1996).”
Plasma amyloid β, apolipoprotein E, lacunar infarcts, and white matter lesions
Van Dijk, E. J., Prins, N. D., Vermeer, S. E., Hofman, A., Van Duijn, C. M., Koudstaal, P. J., & Breteler, M. M. B. (2004) · Annals of Neurology · doi:10.1002/ana.20050 · Cited by 120
The relationship between blood pressure and dementia: a review
Skoog, I. G. (1997) · Biomedicine & Pharmacotherapy · doi:10.1016/s0753-3322(97)89428-0 · Cited by 129
Vaccination with amyloid-beta peptide induces autoimmune encephalomyelitis in C57/BL6 mice
Furlan, R. (2003) · Brain · doi:10.1093/brain/awg031 · Cited by 117
“Furthermore, CNS vessels are a preferential location for the pathological accumulation of amyloid, possibly owing to a site-speci®c abnormal processing of APP (e.g. cerebral amyloid angiopathies) (Suzuki et al., 1994; Thomas et al., 1996).”
BackgroundKLEIN, A. M., KOWALL, N. W., & FERRANTE, R. J. (1999) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1999.tb07845.x · Cited by 115
Amyloid-β Induces Smac Release via AP-1/Bim Activation in Cerebral Endothelial Cells
Yin, K. J., Lee, J.-M., Chen, S. D., Xu, J., & Hsu, C. Y. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-22-09764.2002 · Cited by 117
Soluble Alzheimers β-amyloid constricts the cerebral vasculature in vivo
Suo, Z., Humphrey, J., Kundtz, A., Sethi, F. N., Placzek, A. N., Crawford, F., & Mullan, M. (1998) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00814-3 · Cited by 114
Self-citationAdd Alzheimer's disease to the list of autoimmune diseases
D’Andrea, M. R. (2005) · Medical Hypotheses · doi:10.1016/j.mehy.2004.08.024 · Cited by 113
Alzheimer's Disease, β-Amyloid Protein and Zinc
Huang, X., Cuajungco, M. P., Atwood, C., Moir, R. D., Tanzi, R. E., & Bush, A. I. (2000) · Journal of Nutrition · doi:10.1093/jn/130.5.1488s · Cited by 125
Characteristics of thein VitroVasoactivity of β-Amyloid Peptides
Crawford, F., Suo, Z., Fang, C., & Mullan, M. (1998) · Experimental Neurology · doi:10.1006/exnr.1997.6743 · Cited by 112
Self-citationAβ peptide immunization restores blood‐brain barrier integrity in Alzheimer disease
Dickstein, D. L., Biron, K. E., Ujiie, M., Pfeifer, C. G., Jeffries, A. R., & Jefferies, W. A. (2006) · The FASEB Journal · doi:10.1096/fj.05-3956com · Cited by 111
Oxidative Stress in Alzheimer’s Disease: Should We Keep Trying Antioxidant Therapies?
Ferreira, M. E. S., de Vasconcelos, A. S., Vilhena, T. D. C., da Silva, T. L., Barbosa, A. D. S., Gomes, A. R. Q., Dolabela, M. F., & Percário, S. (2015) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-015-0157-y · Cited by 117
“…1976; Behl and Sagara 1997). bA is itself a source of free radicals because it interacts with endothelial cells to produce excess O 2 •-radicals, which might be an important factor in degenerative processes by inducing oxidative and peroxidative events that lead to cell death (Thomas et al. 1996).”
BackgroundHypertension, hypertension-clustering factors and Alzheimer's disease
Skoog, I., & Gustafson, D. (2003) · Neurological Research · doi:10.1179/016164103101201986 · Cited by 109
Cerebrovascular Degeneration Is Related to Amyloid‐β Protein Deposition in Alzheimer's Diseasea
KALARIA, R. N. (1997) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1997.tb48478.x · Cited by 109
Olichney, J. M., Hansen, L. A., Hofstetter, C. R., Lee, J.-H., Katzman, R., & Thal, L. J. (2000) · Archives of Neurology · doi:10.1001/archneur.57.6.869 · Cited by 108
Type 2 diabetes mellitus, dyslipidemia, and Alzheimer’s disease
Carlsson, C. M. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100012 · Cited by 109
“Physiological levels of soluble Aβ induce dysfunction in cerebral vessels of rats and in cultured endothelial cells [51,52].”
Leo, M. E. D., Borrello, S., Passantino, M., Palazzotti, B., Mordente, A., Daniele, A., Filippini, V., Galeotti, T., & Masullo, C. (1998) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00469-8 · Cited by 108
Alzheimer’ s disease, oxidative stress and gammahydroxybutyrate
Mamelak, M. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.06.008 · Cited by 118
Cerebral blood flow regulation by nitric oxide in neurological disorders
Toda, N., Ayajiki, K., & Okamura, T. (2009) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y09-048 · Cited by 106
Metadata
- Authors
- Thomas, T., Thomas, G., McLendon, C., Sutton, T., & Mullan, M.
- Affiliations
- University of South Florida (US)
- Venue
- Nature
- Published
- 1996-03
- Volume
- 380
- Issue
- 6570
- Pages
- 168-171
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1990427131
- Cited by
- 703
- References
- 12
- Citations by year
- 2026: 7 · 2025: 11 · 2024: 18 · 2023: 22 · 2022: 9 · 2021: 15 · 2020: 24 · 2019: 19 · 2018: 5 · 2017: 12 · 2016: 22 · 2015: 26 · 2014: 16 · 2013: 26 · 2012: 13
- FWCI
- 26.75
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Physiology (medical) › Nitric Oxide and Endothelin Effects
- Health Sciences › Medicine › Biochemistry (medical) › Antioxidant Activity and Oxidative Stress
- Keywords
- amyloid-beta, Alzheimer's disease, vascular endothelial cells, superoxide, free radicals, superoxide dismutase, endothelium-derived relaxing factor, lipid peroxidation, vascular tone, neurodegeneration, aging, oxidative stress
- MeSH terms
- Acetylcholine, Alzheimer Disease, Animals, Aorta, Blood Vessels, Endothelium, Vascular, Nerve Degeneration, Phenylephrine, Superoxides, Vasoconstriction, Vasoconstrictor Agents, Vasodilator Agents, Amyloid beta-Peptides, Rats, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.